LATEX PROCESSING CHEMICALS
http://www.itcilo.it/english/actrav/.../ic/106490.htm
By John G. Downing, M..D.
First Published in the New England Journal of Medicine,
* Highly Toxic or Irritant
* Aniline
* Hexamethyline-tetramine
* Ortho-toluidine
*
* Slightly Toxic or Irritant
* Alpha-naphthylamine
* Beta Methyline aniline
* Para-Phenylinediamine
FROM :-
http://193.51.164.11/htdocs/monograp...ine-ortho.html
Overall evaluation: -
Ortho-Toluidine is possibly carcinogenic
to humans (Group 2B).
Para-toluidine
Inhalation Blue lips or finger nails. Blue skin. Confusion.
Dizziness. Headache. Laboured breathing. Nausea. Shortness of breath.
Unconsciousness. Weakness. Ingestion Blue lips or fingernails. Blue skin.
Dizziness. Headache. Laboured breathing (further see Inhalation).
ROUTES OF EXPOSURE:
The substance can be absorbed into the body by inhalation
and through the skin and by ingestion.
INHALATION RISK:
Evaporation at 20°C is negligible; a harmful concentration
of airborne particles can, however, be reached quickly on spraying or
when dispersed, especially if powdered.
EFFECTS OF SHORT-TERM EXPOSURE:
The substance irritates the eyes and the skin. The substance
may cause effects on the blood, bladder and kidneys , resulting in tissue
lesions and formation of methaemoglobin. Exposure to high concentrations
may result in damage to kidneys and bladder. The effects may be delayed.
Medical observation is indicated. See Notes.
EFFECTS OF LONG-TERM OR REPEATED EXPOSURE:
Repeated or prolonged contact may cause skin sensitization.
The substance may have effects on the blood , resulting in formation of
methaemoglobin (see Notes). The following chemicals are known or suspected
carcinogens. This list has been compiled from a number of sources, but
it is not (and cannot be) comprehensive. Therefore, the absence of a
chemical
from this list does not mean that it cannot have carcinogenic properties.
Neither does the presence of a chemical in the list indicate that it is
a proven carcinogen. However, users should treat
the materials listed with the caution due to suspected carcinogens,
and gather as much safety data as possible before starting work.
Restrictions apply to the use of some of these chemicals
in the U.K. We have done our best to ensure the data below is as accurate
as possible, but cannot accept responsibility for its use or mis-use.
Aniline 4,4'-Methylenedianiline Trichlormethine (Trimustine
hydrochloride)
*
http://physchem.ox.ac.uk/MSDS/carcinogens.html
25249.8.
*
-o0o-
List Of Chemicals Known to Cause Cancer
Or Reproductive Toxicity.
(a) On or before March 1, 1987.
State of California
The Governor shall cause to be published a list of those
chemicals known to the state to cause cancer or
reproductive toxicity within the meaning of this chapter, and he
shall cause such list to be revised and republished in light of additional
knowledge at least once per year thereafter. Such list shall include at
a minimum those substances identified by reference in Labor Code Section
6382(b)(1) and those substances identified additionally by reference in
Labor Code Section 6382(d).
* Aniline 62533 January 1, 1990
* Benzene 71432 February 27, 1987
* Trichlormethine (Trimustine hydrochloride)
817094 January 1, 1992
* 4,4'-Methylenedianiline 101779
January 1, 1988
* 4,4'-Methylenedianiline dihydrochloride
13552448 January 1, 1988
FROM CANCER DATABASE
benzene, aromatic amines – Rubber processing chemicals
Carcinogen
:- lymphatic & haemato-poietic system (leukemia) (bone marrow) bladder
http://www.bccancer.bc.ca/cid/25-3.html
On Wed, 16 Mar 2005 19:15:03 -0500, "PaulKing"
<aimulti@aimultimedia.com> wrote:
So what?
Condom use may PREVENT cancer.
George M. Carter
**
Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC,
Giuliano AR. Condom use and other factors affecting penile human
papillomavirus detection in men attending a sexually transmitted
disease clinic. Sex Transm Dis. 2004 Oct;31(10):601-7.
Department of Obstetrics and Gynecology, University of Arizona College
of Medicine, Tucson, Arizona, USA. sbaldwin@mednet.ucla.edu
BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) is the primary
cause of cervical, anal, and other anogenital cancers, but risk
factors for penile HPV detection in men have not been
well-characterized. GOAL: The goal of this study was to identify
correlates of penile HPV detection in ethnically diverse men attending
a sexually transmitted disease clinic. STUDY: A cross-sectional
investigation was conducted among 393 men. Participants completed a
risk-factor questionnaire and underwent testing for penile HPV DNA.
Presence of HPV DNA was assessed using polymerase chain reaction with
PGMY primers and reverse line blot genotyping. Logistic regression
analyses were conducted to identify variables associated with
any-type, oncogenic, and nononcogenic HPV. RESULTS: Circumcision was
associated with reduced risk for oncogenic, nononcogenic, and overall
HPV. Regular condom use was associated with reduced risk for oncogenic
and overall HPV. CONCLUSION: These findings, if confirmed by other
studies, could impact public health practices and messages regarding
HPV.
**
Snijders PJ, Berkhof J, Westenend PJ, Meijer CJ. Condom use promotes
regression of cervical intraepithelial neoplasia and clearance of
human papillomavirus: a randomized clinical trial. Int J Cancer. 2003
Dec 10;107(5):811-816.
Comment in: * Int J Cancer. 2004 Oct 20;112(1):164; author reply 165.
Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Department
of Gynaecology and Obstetrics, Albert Schweitzer Hospital, Dordrecht,
the Netherlands.
Women with persistent HPV infections have increased risk of
progressive CIN lesions. Transmission of HPV between sexual partners
might maintain viral infection and, consequently, may influence the
clinical course of CIN. We investigated the effect of condom use on
regression of CIN lesions and on clearance of HPV. Women with CIN and
their male sexual partners were randomized for condom use (condom
group n = 72 and noncondom group n = 76). They were conservatively
managed and followed every 3-6 months by colposcopy, cytology and HPV
testing by GP5+/6+ PCR. Baseline cervical biopsy specimens were taken.
Median follow-up time for women was 15.2 months (range 3.0-85.4).
Outcomes of interest were clinical regression of CIN at colposcopy and
clearance of HPV. Outcomes were assessed in 64 women of the condom
group and 61 women of the noncondom group. Women in the condom group
showed a 2-year cumulative regression rate of 53% vs. 35% in the
noncondom group (p = 0.03). The 2-year cumulative rates of HPV
clearance were 23% vs. 4%, respectively (p = 0.02). Although lower
regression rates were found if women were HPV-positive and had > or
=CIN2 lesions at baseline, effects of condom use were found both in
women with CIN1 and in women with > or =CIN2 lesions. Condom use
promotes regression of CIN lesions and clearance of HPV. Copyright
2003 Wiley-Liss, Inc.
